The SLP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SLP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SLP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SLP Detailed Price Forecast - CNN Money||View SLP Detailed Summary - Google Finance|
|View SLP Detailed Summary - Yahoo! Finance||View SLP Stock Research & Analysis - Zacks.com|
|View SLP Trends & Analysis - Trade-Ideas||View SLP Major Holders - Barrons|
|View SLP Call Transcripts - NASDAQ||View SLP Breaking News & Analysis - Seeking Alpha|
|View SLP Annual Report - CompanySpotlight.com||View SLP OTC Short Report - OTCShortReport.com|
|View SLP Fundamentals - TradeKing||View SLP SEC Filings - Bar Chart|
|View Historical Prices for SLP - The WSJ||View Performance/Total Return for SLP - Morningstar|
|View the Analyst Estimates for SLP - MarketWatch||View the Earnings History for SLP - CNBC|
|View the SLP Earnings - StockMarketWatch||View SLP Buy or Sell Recommendations - MacroAxis|
|View the SLP Bullish Patterns - American Bulls||View SLP Short Pain Metrics - ShortPainBot.com|
|View SLP Stock Mentions - StockTwits||View SLP Stock Mentions - PennyStockTweets|
|View SLP Stock Mentions - Twitter||View SLP Investment Forum News - Investor Hub|
|View SLP Stock Mentions - Yahoo! Message Board||View SLP Stock Mentions - Seeking Alpha|
|View Insider Transactions for SLP - SECform4.com||View Insider Transactions for SLP - Insider Cow|
|View SLP Major Holdings Summary - CNBC||View Insider Disclosure for SLP - OTC Markets|
|View Insider Transactions for SLP - Yahoo! Finance||View Institutional Holdings for SLP - NASDAQ|
|View SLP Stock Insight & Charts - FinViz.com||View SLP Investment Charts - StockCharts.com|
|View SLP Stock Overview & Charts - BarChart||View SLP User Generated Charts - Trading View|
DILIsym Awarded $1.5 Million Phase II NIH Grant
Posted on Thursday January 17, 2019
DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded $1.5 million from Phase II of its previously announced Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The second phase of the grant funding will support DILIsym Services’ continued development, validation, and testing of its RENAsym software for predicting drug-induced kidney injury.
Edited Transcript of SLP earnings conference call or presentation 9-Jan-19 9:15pm GMT
Posted on Wednesday January 16, 2019
Q1 2019 Simulations Plus Inc Earnings Call
Simulations Plus Releases DDDPlus™ Version 6
Posted on Tuesday January 15, 2019
Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus™. John DiBella, president of the Lancaster division, added: “The DDDPlus client base has steadily increased over the years, with several regulatory agencies now using the program to assess dissolution method and product specification questions.
DILIsym Services Inc. Initiates Development of IPFsym™
Posted on Monday January 14, 2019
DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it is initiating development of IPFsym™, QSP (quantitative systems pharmacology) modeling software that will provide the ability to predict the efficacy of drugs being developed to treat idiopathic pulmonary fibrosis (IPF). The development of IPFsym is being sponsored by a large pharmaceutical company partner for $2.7 million, and it will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.